Role of ultra-high b-value DWI in the imaging of hereditary leiomyomatosis and renal cell carcinoma (HLRCC).
Diffusion Weighted MRI
Hereditary leiomyomatosis and renal cell cancer
MRI
Renal cancer
Ultrahigh b-value
Journal
Abdominal radiology (New York)
ISSN: 2366-0058
Titre abrégé: Abdom Radiol (NY)
Pays: United States
ID NLM: 101674571
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
15
08
2022
accepted:
16
09
2022
revised:
15
09
2022
pubmed:
8
10
2022
medline:
21
1
2023
entrez:
7
10
2022
Statut:
ppublish
Résumé
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome is associated with an aggressive form of renal cell carcinoma with high risk of metastasis, even in small primary tumors with unequivocal imaging findings. In this study, we compare the performance of ultra-high b-value diffusion-weighted imaging (DWI) sequence (b = 2000 s/mm Twenty-eight patients (n = 18 HLRCC patients with 22 lesions, n = 10 controls) were independently evaluated by three abdominal radiologists with different levels of experience using four combinations of MRI sequences in two separate sessions (session 1: DWI with b-800, session 2: DWI with b-2000). T1 precontrast, T2-weighted (T2WI), and apparent diffusion coefficient (ADC) sequences were similar in both sessions. Each identified lesion was subjectively assessed using a six-point cancer likelihood score based on individual sequences and overall impression. The ability to distinguish benign versus malignant renal lesions improved with the use of b-2000 for more experienced radiologists (Reader 1 AUC: Session 1-0.649 and Session 2-0.938, p = 0.017; Reader 2 AUC: Session 1-0.781 and Session 2-0.921, p = 0.157); whereas no improvement was observed for the less experienced reader (AUC: Session 1-0.541 and Session 2-0.607, p = 0.699). The inclusion of ultra-high b-value DWI sequence improved the ability of classification of renal lesions in patients with HLRCC for experienced radiologists. Consideration should be given toward incorporation of DWI with b-2000 s/mm
Identifiants
pubmed: 36207629
doi: 10.1007/s00261-022-03689-w
pii: 10.1007/s00261-022-03689-w
pmc: PMC10681094
mid: NIHMS1941605
doi:
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
340-349Subventions
Organisme : Intramural NIH HHS
ID : Z01 BC011028
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA BC012062
Pays : United States
Informations de copyright
© 2022. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Références
Am J Hum Genet. 2003 Jul;73(1):95-106
pubmed: 12772087
J Natl Compr Canc Netw. 2022 Jan;20(1):71-90
pubmed: 34991070
J Magn Reson Imaging. 2015 Jul;42(1):80-6
pubmed: 25223489
Fam Cancer. 2020 Jan;19(1):55-63
pubmed: 31792767
Oncol Lett. 2019 Aug;18(2):1451-1457
pubmed: 31423210
Abdom Radiol (NY). 2016 Oct;41(10):1997-2010
pubmed: 27271218
Clin Imaging. 2020 Dec;68:14-19
pubmed: 32562921
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Fam Cancer. 2014 Dec;13(4):637-44
pubmed: 25012257
Acta Radiol. 2014 Sep;55(7):882-9
pubmed: 24092760
Cancer Imaging. 2021 Feb 19;21(1):24
pubmed: 33608050
Int J Nephrol Renovasc Dis. 2014 Jun 20;7:253-60
pubmed: 25018647
Invest Radiol. 2021 Oct 1;56(10):629-636
pubmed: 34494995
Acta Radiol. 2018 Jan;59(1):105-113
pubmed: 28376634
BMC Cancer. 2014 Nov 18;14:843
pubmed: 25406910
Abdom Radiol (NY). 2019 Nov;44(11):3595-3605
pubmed: 31444557
J Magn Reson Imaging. 2019 Jan;49(1):23-40
pubmed: 30311988
Anticancer Res. 2018 Feb;38(2):969-978
pubmed: 29374729
Urol Oncol. 2017 Jul;35(7):473-491
pubmed: 28506596
Radiographics. 2011 Oct;31(6):1773-91
pubmed: 21997994
Nat Genet. 2002 Apr;30(4):406-10
pubmed: 11865300
Genes (Basel). 2021 Feb 11;12(2):
pubmed: 33670168
J Magn Reson Imaging. 2013 Sep;38(3):694-700
pubmed: 23371846